MANIFEST: Multiomic platform for cancer immunotherapy

https://doi-org.manchester.idm.oclc.org/10.1158/2159-8290.CD-25-0099 1st May 2025

Article highlights & insights

Immunotherapy has revolutionised survival outcomes for many patients diagnosed with cancer. However, biomarkers that can reliably distinguish treatment responders from nonresponders, predict potential life-threatening and life-changing drug-induced toxicities, or rationalise treatment choices are still lacking. In response to this unmet clinical need, we introduce Multiomic ANalysis of Immunotherapy Features Evidencing Success and Toxicity, a tumour type-agnostic platform to provide deep profiling of patients receiving immunotherapy that will enable integrative identification of biomarkers and discovery of novel targets using artificial intelligence and machine learning.

Gloved hands filling a stripette white lab coat

Latest from CRUK MI

Cancer Research In the Paterson Building

Find out more about the facilities across the Institute

Leukaemia Immunology & Transplantation

The Leukaemia Immunology and Transplantation laboratory aim to develop a comprehensive strategy to prevent post-transplant relapse in patients treated with allogeneic haematopoietic stem cell transplantation – the only curative therapy for many patients with acute myeloid leukaemia (AML) and other poor-risk haematological malignancies.

Patient derived preclinical models reveal novel biology of SCLC

Immune detection of dying tumour cells can elicit cancer immunity when the host permits it

Cancer Research In the Paterson Building
Leukaemia Immunology & Transplantation
Patient derived preclinical models reveal novel biology of SCLC